Global Head Clinical Pharmacology F Hoffmann la Roche Ltd Basel, Switzerland
Potential treatments for COVID-19 are being investigated at unprecedented speed and successful treatments will rapidly be used in tens or hundreds of thousands of patients. To ensure safe and effective use in all those patents it is essential also to develop, at unprecedented speed, a means to provide frequently updated, optimal dosing information for all patient subgroups. Success will require immediate collaboration between drug developers, academics and regulators.
Learn how M&S and real world data can potentially be leveraged to acceoerate understanbding of dose individualisation needed to use emerging treatments for COVID-19 safely and effectively in all patents.
Understand the importance of industry, academic and health industry collaboration.
Identify if andf how they can help to drive this evolution to support identifying the best dose for each patient with COVID-19.